Education
About Us
Working with TipRanks
Follow Us
Alembic Limited (IN:ALEMBICLTD)
:ALEMBICLTD
Top Page
Alembic Limited
(ALEMBICLTD)
Rating:68Neutral
Price Target:
₹126.00
▲(19.89% Upside)
Alembic Limited (ALEMBICLTD) vs. iShares MSCI India ETF (INDA)
Market Cap
₹27.86B
Dividend Yield2.21%
Average Volume (3M)33.60K
Price to Earnings (P/E)8.8
Beta (1Y)1.44
Revenue Growth28.84%
EPS Growth13.01%
CountryIN
Employees285
SectorHealthcare
Sector Strength41
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.40
Shares Outstanding256,781,830
10 Day Avg. Volume30,126
30 Day Avg. Volume33,604
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹126.00Price Target Upside19.89% Upside
Rating ConsensusHold
Number of Analyst Covering1
Alembic Limited Business Overview & Revenue Model
Company DescriptionAlembic Limited is a leading pharmaceutical company based in India, engaged in the development, manufacturing, and marketing of generic pharmaceutical products. Established in 1907, the company has a significant presence in both domestic and international markets. Alembic's core product offerings include active pharmaceutical ingredients (APIs), formulations, and over-the-counter (OTC) products, catering to a wide range of therapeutic segments.
How the Company Makes MoneyAlembic Limited generates revenue primarily through the sale of its pharmaceutical products, including APIs and finished formulations. The company's revenue streams are diversified across domestic and international markets, with a strong focus on exports to regulated markets such as the United States and Europe. Key factors contributing to Alembic's earnings include its robust product pipeline, strategic partnerships with global pharmaceutical companies, and investments in research and development to innovate and expand its product portfolio. Additionally, Alembic leverages its manufacturing capabilities to offer contract manufacturing services, further enhancing its revenue potential.
Alembic Limited Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.22B | 1.47B | 1.18B | 713.69M | 678.37M |
| Gross Profit | 1.53B | 872.46M | 702.07M | 404.50M | 392.74M |
| EBITDA | 1.69B | 1.05B | 939.86M | 1.03B | 213.43M |
| Net Income | 3.11B | 2.69B | 1.91B | 2.22B | 3.43B |
Balance Sheet | |||||
| Total Assets | 25.03B | 23.29B | 22.05B | 26.32B | 24.09B |
| Cash, Cash Equivalents and Short-Term Investments | 626.60M | 129.05M | 464.09M | 270.77M | 225.14M |
| Total Debt | 144.50M | 91.49M | 0.00 | 0.00 | 2.77M |
| Total Liabilities | 1.64B | 1.43B | 1.27B | 1.35B | 1.12B |
| Stockholders Equity | 23.39B | 21.86B | 20.78B | 24.97B | 22.97B |
Cash Flow | |||||
| Free Cash Flow | 356.00M | -336.03M | 130.35M | -535.60M | -496.37M |
| Operating Cash Flow | 863.70M | 226.87M | 388.52M | -177.47M | -21.82M |
| Investing Cash Flow | -265.80M | 258.36M | 72.96M | 188.48M | -348.69M |
| Financing Cash Flow | -583.40M | -481.94M | -463.88M | -58.16M | -153.62M |
Alembic Limited Technical Analysis
Negative
105.10
Price Trends
112.92
Negative
107.19
Positive
112.95
Negative
Market Momentum
-1.48
Positive
43.15
Neutral
22.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALEMBICLTD, the sentiment is Negative. The current price of 105.1 is below the 20-day moving average (MA) of 112.57, below the 50-day MA of 112.92, and below the 200-day MA of 112.95, indicating a bearish trend. The MACD of -1.48 indicates Positive momentum. The RSI at 43.15 is Neutral, neither overbought nor oversold. The STOCH value of 22.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALEMBICLTD.
Alembic Limited Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹615.84B | 26.96 | 0.83% | 4.49% | 11.22% | ||
71 Outperform | ₹614.49B | 18.12 | 0.38% | 7.76% | -2.83% | ||
68 Neutral | ₹27.86B | 8.80 | 2.21% | 28.84% | 13.01% | ||
66 Neutral | ₹349.17B | 44.84 | 0.29% | 11.49% | 35.00% | ||
62 Neutral | ₹580.50B | 55.43 | 0.12% | 9.39% | ― | ||
59 Neutral | ₹186.09B | 30.86 | 1.16% | 8.20% | -4.26% | ||
51 Neutral | $7.42B | -0.36 | -40.86% | 2.27% | 22.89% | -2.16% |
* Healthcare Sector Average
Performance Comparison
IN:ALEMBICLTD
Alembic Limited
105.10
-32.11
-23.40%
IN:ALKEM
Alkem Laboratories Ltd.
5,390.90
-237.78
-4.22%
IN:APLLTD
Alembic Pharmaceuticals Limited
943.60
-106.02
-10.10%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,077.15
-436.37
-28.83%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,031.80
542.93
36.47%
IN:IPCALAB
IPCA Laboratories Limited
1,364.10
17.00
1.26%
Alembic Limited Corporate Events
Alembic Limited Updates Registrar Contact Details
Apr 18, 2025
Alembic Limited announced a change in the email and website address of its Registrar and Share Transfer Agent, MUFG Intime India Private Limited. This update is part of a continued effort to streamline communication and improve service efficiency for shareholders, reflecting the company’s commitment to maintaining effective stakeholder relations.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.